This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 10:15, 17 February 2011 (Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 10:15, 17 February 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation ()(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound| Clinical data | |
|---|---|
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 1.5–2.5 hours |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C305H442N88O91S8 |
| Molar mass | 7053.83 g/mol (7053 Da) g·mol |
| (verify) | |
Ecallantide (trade name Kalbitor, investigational name DX-88) is an inhibitor of the protein kallikrein used for hereditary angioedema (HAE) and in the prevention of blood loss in cardiothoracic surgery. It is a 60-amino acid polypeptide which was developed from a Kunitz domain through phage display to mimic antibodies inhibiting kallikrein. On November 27, 2009, ecallantide was approved by the U.S. Food and Drug Administration for the treatment of acute attacks of hereditary angioedema.
If approved for cardiothoracic surgery, it could become a replacement for aprotinin, which was withdrawn in 2007 after being shown to cause complications.
See also
- Icatibant, another drug for the treatment of HEA
References
- "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ Lehmann A (2008). "Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery". Expert Opin Biol Ther. 8 (8): 1187–99. doi:10.1517/14712598.8.8.1187. PMID 18613770.
{{cite journal}}: Unknown parameter|month=ignored (help) - Waknine, Yael (December 4, 2009). "FDA Approves Ecallantide for Hereditary Angioedema". Medscape. Retrieved 2009-12-07.
- Kalbitor Advisory Committee Briefing Document, Dyax Corp., accessed February 11, 2009
- http://www.medscape.com/viewarticle/587866?src=mp&spon=38&uac=33931AT, accessed February 11, 2009
 | This drug article relating to the blood and blood forming organs is a stub. You can help Misplaced Pages by expanding it. |